Add to ORKGA major concern of HIV dual therapy is a potential lower efficacy in viral reservoirs, especially in the central nervous system (CNS). We evaluated HIV RNA, neuronal injury and inflammatory biomarkers and dolutegravir (DTG) exposure in cerebrospinal fluid (CSF) in patients switching to DTG+lamivudine (3TC). All participants maintained viral suppression in plasma and CSF at week 48. We observed no increase in CSF markers of inflammation or neuronal injury. Median (IQR) total and unbound DTG in CSF were 7.3(5.9-8.4) ng/mL and 1.7(1.2-1.9) ng/mL, respectively. DTG+3TC may maintain viral control without changes in inflammatory/injury markers within the CNS reservoir
OBJECTIVES: To determine HIV-1 RNA in cerebrospinal fluid (CSF) of successfully treated patients and...
HIV-1 invades the central nervous system (CNS) early in the infectious course. It establishes a chro...
Although antiretroviral therapy (ART) can effectively inhibit replication of human immunodeficiency ...
Background: Antiretroviral treatment (ART) significantly reduces cerebrospinal fluid (CSF) HIV-1 RNA...
Despite successful antiretroviral therapy (ART), mild cognitive impairments remain prevalent amongst...
Objectives: The aim of the study was to evaluate HIV-1 viral load (VL) and inflammatory markers in c...
Background Before the introduction of combination antiretroviral therapy (CART), neurological disea...
(See the editorial commentary by McArthur and Letendre, on pages 1628–31.) Objective. To characteriz...
Human immunodeficiency virus type 1 (HIV) enters the central nervous system (CNS) as early as eight ...
OBJECTIVE: To determine changes of cerebrospinal fluid (CSF) biomarkers of patients on monotherapy w...
Objective: To determine changes of cerebrospinal fluid (CSF) biomarkers of patients on monotherapy w...
Objectives: To determine HIV-1 RNA in cerebrospinal fluid (CSF) of successfully treated patients and...
Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low...
Objective: To characterize the evolution of central nervous system (CNS) inflammation in HIV-1 infec...
BackgroundDolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase in...
OBJECTIVES: To determine HIV-1 RNA in cerebrospinal fluid (CSF) of successfully treated patients and...
HIV-1 invades the central nervous system (CNS) early in the infectious course. It establishes a chro...
Although antiretroviral therapy (ART) can effectively inhibit replication of human immunodeficiency ...
Background: Antiretroviral treatment (ART) significantly reduces cerebrospinal fluid (CSF) HIV-1 RNA...
Despite successful antiretroviral therapy (ART), mild cognitive impairments remain prevalent amongst...
Objectives: The aim of the study was to evaluate HIV-1 viral load (VL) and inflammatory markers in c...
Background Before the introduction of combination antiretroviral therapy (CART), neurological disea...
(See the editorial commentary by McArthur and Letendre, on pages 1628–31.) Objective. To characteriz...
Human immunodeficiency virus type 1 (HIV) enters the central nervous system (CNS) as early as eight ...
OBJECTIVE: To determine changes of cerebrospinal fluid (CSF) biomarkers of patients on monotherapy w...
Objective: To determine changes of cerebrospinal fluid (CSF) biomarkers of patients on monotherapy w...
Objectives: To determine HIV-1 RNA in cerebrospinal fluid (CSF) of successfully treated patients and...
Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low...
Objective: To characterize the evolution of central nervous system (CNS) inflammation in HIV-1 infec...
BackgroundDolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase in...
OBJECTIVES: To determine HIV-1 RNA in cerebrospinal fluid (CSF) of successfully treated patients and...
HIV-1 invades the central nervous system (CNS) early in the infectious course. It establishes a chro...
Although antiretroviral therapy (ART) can effectively inhibit replication of human immunodeficiency ...